A review of pathophysiology and therapy of patients with vasovagal syncope

Pharmacotherapy

Volumn 20, Issue 2, 2000, Pages 158-165

  White, C Michael ^a,b   Tsikouris, James P ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ESMOLOL; FLUOXETINE; GRANISETRON; ISOPRENALINE; METOPROLOL; PAROXETINE; PROPRANOLOL; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADRENERGIC SYSTEM; ADULT; CHOLINERGIC ACTIVITY; DRUG EFFICACY; HEAD TILTING; HUMAN; PATHOPHYSIOLOGY; REVIEW; SEROTONINERGIC SYSTEM; SYNCOPE;

EID: 0033968521     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.3.158.34786     Document Type: Review

References (72)

1. Anonymous. Dorland's illustrated medical dictionary, 27th ed. Philadelphia: WB Saunders, 1988.
2. Kapoor WN. Evaluation and outcome of patients with syncope Medicine 1990;69:160-75.
3. Savage DD, Corwin L, McGee DL, Kannel WB, Wolf PA. Epidemiologic features of isolated syncope: the Framingham study. Stroke 1985;16:626-9.
4. Litsitz LA, Wei JY, Rowe JW. Syncope in an elderly, institutionalized, population: prevalence, incidence, and associated risk. Q J Med 1985;216:45-55.
5. Wolfe DA, Grubb BP, Limrel SR. Head-upright tilt testing: a new method of evaluating syncope. Am Fam Physician 1993;47:149-59.
6. Kapoor W, Peterson J, Wieand HS, Karpf M. Diagnostic and prognostic implications of recurrences in patients with syncope. Am J Med 1987;83:700-8.
7. Manolis AS, Linzer M, Salem D, Estes M. Syncope: current diagnosis, evaluation and management. Ann Intern Med 1990;112:850-63.
8. Kligfield P. Tilt table for the investigation of syncope: there is nothing simple about fainting. J Am Coll Cardiol 1991;17:131-2.
9. Hammill SC, Thomas JE. Syncopal disorders. In: Guilliani ER, Gersh BJ, McGoon MD, Hayes DL, Schaff HV, eds. Mayo Clinic practice of cardiology. St Louis: CV Mosby, 1996:849-61.
10. Van Lieshout JJ, Weiling W, Karemaker JM. Neural circulatory control in vasovagal syncope. Pacing Clin Electrophysiol 1997;20(pt II):753-63.
11. Lazarus JC, Mauro VF. Syncope: pathophysiology, diagnosis, and pharmacotherapy. Ann Pharmacother 1996;30:994-1005.
12. Anonymous. Heart failure. In: Lilly LS, ed. Pathophysiology of heart disease. Boston: Lea & Febiger, 1993:147-66.
13. Quan KJ, Carlson MD, Thames MD. Mechanisms of heart rate and arterial blood pressure control: implications for the pathophysiology of neurocardiogenic syncope. Pacing Clin Electrophysiol 1997;20(pt II):764-74.
14. Morito H, Vatner SF. Effects of hemorrhage on renal nerve activity in conscious dogs. Circ Res 1985;57:788-93.
15. Skoog P, Mansson J, Thoren P. Changes in renal sympathetic outflow during hypotensive haemorrhage in rats. Acta Physiol Scand 1985;125:655-60.
16. Prinz-Zaiss M, Yeap N, Moguilevski V, Trigg L, Mcgrath BP. Presyncopal sympathetic withdrawal is the same in patients with vasodepressor syncope and controls who faint on head-up tilting. Am Heart J 1997;133:230-9.
17. Dietz NM, Joyner MJ, Shepherd JT. Vasovagal syncope and skeletal muscle vasodilatation: the continuing conundrum. Pacing Clin Electrophysiol 1997;20(pt 2):755-80.
18. Henderson MC, Prabhu SD. Syncope: current diagnosis and treatment. Curr Probl Cardiol 1997;22(5):243-96.
19. Shalev Y, Gal R, Tchou P, et al. Echocardiographic demonstration of decreased left-ventricular dimensions and vigorous myocardial contraction during syncope induced by head upright tilt. J Am Coll Cardiol 1991;18:748-51.
20. Grubb BP, Kosinski D. Tilt table testing: concepts and limitations. Pacing Clin Electrophysiol 1997;20(pt II):781-7.
21. Chen MY, Goldenberg IF, Milstein S, et al. Cardiac electrophysiologic and hemodynamic correlates of neurally mediated syncope. Am J Cardiol 1989;63:66-72.
22. Thames MD, Abboud FM. Reflex inhibition of renal sympathetic nerve activity during myocardial ischemia mediated by left ventricular receptors with vagal afferents in dogs. J Clin Invest 1979;63:395-402.
23. Thoren PN. Activation of the left-ventricular receptors with nonmedullated vagal afferent fibers during occlusion of a coronary artery in the cat. Am J Cardiol 1976;37:1046-51.
24. Schadt JC, Ludbrook J. Hemodynamic and neurohormonal responses to acute hypovolemia in conscious mammals. Am J Physiol 1991;260(suppl 29):H305-18.
25. Lathers CM, Charles JB, Schneider VS, Frey MA, Fortney S. Use of lower body negative pressure to assess changes in heart rate response to orthostatic-like stress during 17 weeks of bed rest. J Clin Pharmacol 1994;34:563-70.
26. Charles JB, Lathers CM. Summary of lower body negative pressure experiments during space flight. J Clin Pharmacol 1994;34:571-83.
27. Piwinski SE, Jankovic J, McElligott MA. A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha-agonist midodrine for these conditions. J Clin Pharmacol 1994;34:466-71.
28. Almquist A, Goldenberg IF, Milstein S, et al. Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. N Engl J Med 1989;320:346-51.
29. Pavri BB, Ruskin JN, Brooks R. The yield of head-up tilt testing is not significantly increased by repeating the baseline test. Clin Cardiol 1996;19:494-6.
30. Kapoor WN, Brant N. Evaluation of syncope by upright tilt testing with isoproterenol: a nonspecific test. Ann Intern Med 1992;116:358-63.
31. Grubb BP, Temesy-Armos P, Hahn H, et al. Utility of upright tilt-table testing in the evaluation and management of syncope of unknown origin. Am J Med 1991;90:6-10.
32. Aerts A, Dendale P, Strobel G, Block P. Sublingual nitrates during head-up tilt testing for the diagnosis of vasovagal syncope. Am Heart J 1997;133:504-7.
33. McEvoy GK, Litvak K, Welsh OH Jr, eds. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1999.
34. Theodorakis GN, Kremastinos DT, Stefankis GS, et al. The effectiveness of β blockade and its influence on heart rate variability in vasovagal patients. Eur Heart J 1993;14:1499-1507.
35. Scott WA, Pongiglione G, Bromberg BI, et al. Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope. Am J Cardiol 1995;76:400-2.
36. Sra JS, Murphy VS, Jazayeri MR, et al. Use of intravenous esmolol to predict efficacy of oral β-adrenergic blocker therapy in patients with neurocardiac syncope. J Am Coll Cardiol 1992;19:402-8.
37. Lippman N, Stein KM, Lerman BB. Differential therapeutic responses of patients with isoproterenol-dependent and isoproterenol-independent vasodepressor syncope. Am Heart J 1994;128:1110-16.
38. Natalie A, Dhala A, Wase A, et al. Efficacy of different treatment strategies for neurocardiac syncope. Pacing Clin Electrophysiol 1995;18(pt 1):655-62.
39. Leor J, Rotstein Z, Vered Z, et al. Absence of tachycardia during tilt test predicts failure of β-blocker therapy in patients with neurocardiogenic syncope. Am Heart J 1994;127:1539-43.
40. Kluger J, Bazunga M, Goldman R, O'Rangers E, Azar P, Chow MS. Usefulness of intravenous metoprolol to prevent syncope induced by head-up tilt. Am J Cardiol 1998;83:820-3.
41. Wang CC, Yeh SJ, Wen MS, Lin FC, Wu D. Worsening of vasovagal syncope after β-blocker therapy. Chest 1994;106:963-5.
42. U.S. Pharmacopeia. Drug information for the health care professional, vol 1. Taunton, MA: Rand McNally, 1995.
43. Lewis T. Vasovagal syncope and the carotid sinus mechanism with components on Gower's and Nothangel's syndrome. Br Med J 1932;1:873-6.
44. McLaran CJ, Gersh BJ, Osborn MJ, et al. Increased vagal tone as an isolated finding in patients undergoing electrophysiological testing for anticholinergic agents. Br Heart J 1986;55:53-7.
45. Benditt DG, Sutton R, Gammage MD, et al. Clinical experience with Thera DR rate drop response pacing algorithm in carotid sinus syndrome and vasovagal syncope. Pacing Clin Electrophysiol 1997;20(pt II):832-9.
46. Connolly SJ, Sheldon R, Roberts RS, Gent M. The North American vasovagal pacemaker study (VPS): a randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol 1999;33:16-20.
47. Abi-Samara F, Maloney JD, Fouad-Tarazi FM, Castle LW. The usefulness of head-up tilt testing and hemodynamic investigations in the work-up of syncope of unknown origin. Pacing Clin Electrophysiol 1988;21:1202-14.
48. Grubb BP, Temesy-Armos PN, Samoil D, Wolfe DA, Hahn H, Eliot L. Tilt-table testing in the evaluation and management of athletes with recurrent exercise induced syncope. Med Sci Sports Exerc 1993;25:24-8.
49. Grubb BP, Temesy-Armos PN, Samoil D, Wolfe DA, Hahn H, Eliot L. The use of head-upright tilting in the evaluation and management of syncope in children and adolescents. Pacing Clin Electrophysiol 1992;15:742-8.
50. Kelly PA, Mann DE, Adler SW, Fuenzalida CE, Reiter MJ. Low dose disopyramide often fails to prevent neurogenic syncope during head-up tilt testing. Pacing Clin Electrophysiol 1994;17(pt 1):573-6.
51. Milstein S, Buetikofer J, Dunningan A, Benditt DG, Gornick C, Reyes WJ. Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia. Am J Cardiol 1990;65:1339-44.
52. Janosik D, Holt D, Fredman C, et al. Efficacy of oral ephedrine sulfate in preventing neurocardiogenic syncope [abstr]. Circulation 1991;84(suppl 11):11-234.
53. Onrot J, Goldberg MR, Hollister AS, et al. Management of chronic orthostatic hypotension. Am J Med 1986;80:454-64.
54. Nelson SD, Stanley M, Love CJ, et al. The autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope. Arch Intern Med 1991;151:2425-9.
55. Flammang D, Luizy J, Waynberger M. Re-initiation and quantification of the vaso-vagal syndrome by the adenosine 5′triphosphate (ATP) test. Assessment of the best therapy [abstr]. Pacing Clin Electrophysiol 1990;13:539.
56. Petersen MEV, Chamberlain-Webber R, Fitzpatrick AP, et al. Permanent pacing for cardioinhibitory malignant vasovagal syndrome. Br Heart J 1994;71:274-81.
57. Shah CP, Thakar RK, Xie B, et al. Dual chamber pacing for neurally mediated syncope with a prominent cardioinhibitory component. Pacing Clin Electrophysiol 1999;22(7):999-1003.
58. Sheldon RS, Koshman ML, Wilson W, et al. Utility of dual chamber pacing with automatic rate-drop sensing in the prevention of neurally mediated syncope. Am J Cardiol 1998;81(2):158-62.
59. Eglen RM, Lee CH, Khabbaz M, et al. Comparison of potencies of 5-HT3 receptor antagonists at inhibiting aversion behavior to illumination and the von Bezold-Jarisch reflex in the mouse. Neuropharmacology 1994;33:227-34.
60. Morgan DA, Thoren P, Wilczynski EA, Victor RG, Mark AL. Serotonergic mechanisms mediate renal sympathoinhibition during severe hemorrhage in rats. Am J Physiol 1988;255(suppl 24):H496-502.
61. Bradley PB, Engel G, Feniuk W, et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986;25:563-76.
62. White CM, Chow MS, Fan C, Kluger J, Bazunga M. Efficacy of intravenous granisetron in suppressing the bradycardia and hypotension associated with a rabbit model of the Bezold-Jarisch reflex. J Clin Pharmacol 1998;38:172-7.
63. Whelan BA, Iriepa I, Galves E, et al. Synthesis and structural, conformational, biochemical, and pharmacological study of new compounds derived from tropane-3-spiro-4-imidazoline as potential 5-HT3 receptor antagonists. J Pharm Sci 1995;84:101-6.
64. Yamano M, Ito H, Kamato T, Miyata K. Species difference in the 5-hydroxytryptamine 3 receptor associated with the von Bezold-jarisch reflex. Arch Int Pharmacodyn Ther 1995;330: 177-89.
65. Mao HZ, Li Z, Chapleau MW. Platelet activation in carotid sinuses triggers reflex sympathoinhibition and hypotension. Hypertension 1996;27(pt 2):584-90.
66. Tadepalli AS, Mills E, Schanberg SM. Central depression of carotid baroreceptor pressor response, arterial pressure, and heart rate by 5-hydroxytryptophan: influence of supracollicular areas of the brain. J Pharmacol Exp Ther 1977;202:310-19.
67. Elam R, Bergmann F, Feurstein G. The use of antiserotonergic agents for the treatment of acute hemorrhagic shock of cats. Eur J Pharmacol 1985;107:275-8.
68. White CM, Tsikouris JP, Chow MSS, Kluger J. Effect of the serotonin receptor antagonist granisetron on neurally mediated syncope [abstr]. Pacing Clin Electrophysiol 1999;22:791.
69. Moran A, Velasco C, Martin ML, San Roman L. Pharmacological characterization of 5-T receptors in parasympathetic innervation of the rat heart. Eur J Pharmacol 1994;252:161-6.
70. Grubb BP, Wolfe DA, Samoil D, Temesy-Armos P, Elliot L. Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope. Pacing Clin Electrophysiol 1993;16(pt 1):458-64.
71. Grubb BP, Samoil D, Kosinski D, Kip K, Brewster P. Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents. J Am Coll Cardiol 1994;24:490-4.
72. DiGirolamo E, Dilorio C, Sabatini P, Leonzio L, Barbone C, Barsotti A. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double blind, placebo-controlled study. J Am Coll Cardiol 1999;33:1227-30.